ArticleLipids in health and disease2018
The influence of the intestinal microflora to the efficacy of Rosuvastatin.
Article in Lipids in health and disease, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 2 syntheses or guidelines pooled it, 29 citations in OpenAlex.
- A Systematic Review of Statins for the Treatment of Nonalcoholic Steatohepatitis: Safety, Efficacy, and Mechanism of Action.Molecules (Basel, Switzerland) · 2024Pooled it
- Gut bacterial microbiome composition and statin intake-A systematic review.Pharmacology research & perspectives · 2020Pooled it
- Microbes and medicines: interrelationships between pharmaceuticals and the gut microbiome.Gut microbes · 2026Review
- Microbiome-Associated Drug Response Variability in Heart Failure Treatment.Life (Basel, Switzerland) · 2026Review
- Drugs Versus Microbiota: How Pharmacotherapy Affects Gut and Probiotic Bacteria.Pharmaceuticals (Basel, Switzerland) · 2025Review
- The Role of Gut Microbiota in the Etiopathogenesis of Multiple Chronic Diseases.Antibiotics (Basel, Switzerland) · 2024Review
- Ceftriaxone-associated dysbiosis decreases voriconazole bioavailability by upregulating intestinal P-glycoprotein expression through activation of the Nrf2-mediated signalling pathway.Frontiers in pharmacology · 2024Article
- Role of Gut Microbiome in Atherosclerosis: Molecular and Therapeutic Aspects.Current cardiology reviews · 2023Review
- Gut microbiota specifically mediates the anti-hypercholesterolemic effect of berberine (BBR) and facilitates to predict BBR's cholesterol-decreasing efficacy in patients.Journal of advanced research · 2022Article
- Role of the gut microbiome in cardiovascular drug response: The potential for clinical application.Pharmacotherapy · 2022Review
- Interplays between drugs and the gut microbiome.Gastroenterology report · 2022Review
- The promise of the gut microbiome as part of individualized treatment strategies.Nature reviews. Gastroenterology & hepatology · 2022Review
- Fructooligosaccharides enhance the therapeutic effect of xiao-zhi-fang on non-alcoholic fatty liver disease via regulating intestinal flora.Liver research (Beijing, China) · 2021Article
- Interactions Between Therapeutics for Metabolic Disease, Cardiovascular Risk Factors, and Gut Microbiota.Frontiers in cellular and infection microbiology · 2020Review
- Targeting gut microbiota for precision medicine: Focusing on the efficacy and toxicity of drugs.Theranostics · 2020Review
- A gut feeling of statin.Gut microbesReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundIntestinal microflora has been shown to play essential roles in the clinical therapies of metabolic diseases. The present study is aiming to investigate the potential roles and mechanisms of how intestinal microflora mediates lipid-reduction efficacy of Rosuvastatin.
methodsTo investigate the correlation between the intestinal microflora and efficacy of Rosuvastatin, we analyzed the diversity of intestinal microflora using PCR-DGGE analysis and 16S rDNA sequencing approaches. Furthermore, we compared the blood lipid levels of rat models with dysbiosis of intestinal microflora and control rats upon the Rosuvastatin administration.
resultsThe diversity of the intestinal flora was obviously decreased upon the antibiotic treatment, this effect could be maintained for 2 weeks after establishment of the models. Importantly, the results from 16S rDNA sequencing demonstrated that the abundance of Lactobacillus and Bifidobacterium was remarkably diminished upon the antibiotic treatment in antibiotic+Rosuvastatin-treated group compared to that of Rosuvastatin-treated group and control group. Correspondently, the lipid-reduction efficacy of Rosuvastatin was significantly compromised. However, the diversity of the intestinal flora was recovered 4 weeks after the antibiotic treatment. Subsequently, the lipid-reduction efficacy of Rosuvastatin was also recovered to level of the control rats treated with Rosuvastatin alone.
conclusionIntestinal flora could play an essential role in mediating the lipid-reduction efficacy of Rosuvastatin.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.